Search
ATP
go.drugbank.com/drugs/DB00171InvestigationalNutraceuticalAn adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnPyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate.
IPH 2101
go.drugbank.com/drugs/DB06049InvestigationalIPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Sulfanilamide
go.drugbank.com/drugs/DB00259ApprovedWithdrawnSulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
Elacytarabine
go.drugbank.com/drugs/DB05494InvestigationalElacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Taliglucerase alfa
go.drugbank.com/drugs/DB08876ApprovedIt was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
DPI-221
go.drugbank.com/drugs/DB06121ExperimentalDPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.
Synonyms: .-((2S,5R)-2,5-DIMETHYL-4-(3-FLUOROBENZYL)-1-PIPERAZINYL)BENZYL)-N,N-DIETHYLBENZAMIDE, BENZAMIDE, N,N-DIETHYL-4-((S)-((2S,5R)-4-((3-FLUOROPHENYL)METHYL)-2,5-DIMETHYL-1-PIPERAZINYL)PHENYLMETHYL)-T611
go.drugbank.com/drugs/DB06391ExperimentalT611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.
SP1049C
go.drugbank.com/drugs/DB04978ExperimentalPreliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.
Categories: Compounds used in a research, industrial, or household setting